Deerfield Management Company, L.P. (Series C) Recursion Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,315,000 shares of RXRX stock, worth $14.3 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
2,315,000Holding current value
$14.3 Million% of portfolio
0.28%Shares
1 transactions
Others Institutions Holding RXRX
# of Institutions
286Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$203 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$156 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$150 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$107 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$95.1 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.12B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...